Compare SDA & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDA | BNR |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | China | China |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | 94.4M |
| IPO Year | 2022 | 2019 |
| Metric | SDA | BNR |
|---|---|---|
| Price | $0.72 | $9.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.75 | N/A |
| AVG Volume (30 Days) | ★ 55.3K | 4.2K |
| Earning Date | 04-28-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.01 | $111.65 |
| Revenue Next Year | $15.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $6.79 |
| 52 Week High | $2.93 | $41.72 |
| Indicator | SDA | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 38.89 | 53.93 |
| Support Level | $0.72 | $8.69 |
| Resistance Level | $0.86 | $10.00 |
| Average True Range (ATR) | 0.06 | 0.52 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 2.33 | 50.58 |
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform. Revenues from its continuing operations are mainly generated from providing auto eInsurance services, technology services, and auto services.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.